<DOC>
	<DOCNO>NCT02649283</DOCNO>
	<brief_summary>This Phase IV , multicenter , open label , non-randomized comparative group study assess safety performance OrbiSymm system subject refer contra lateral breast symmetrization involve breast reduction follow breast reconstruction post-mastectomy .</brief_summary>
	<brief_title>Performance OrbiSymm Subjects Referred Contra Lateral Breast Symmetrisation</brief_title>
	<detailed_description>The device CE Mark use indication approve . Up 60 patient assign study ( 30 patient Orbix procedure , 30 patient without Orbix procedure ( routine reduction/symmetrisation ) . Patients return clinic follow-up 1 , 3 , 6 , 12 &amp; 24 month ( last visit optional ) .</detailed_description>
	<criteria>1 . Signed informed consent study specific test procedures do . 2 . Female subject age 20 65 year old 3 . Underwent breast reconstruction follow unilateral mastectomy refer contra lateral symmetrisation procedure require reduction least 150gr ( clarification : procedure reconstruction symmetrisation may perform simultaneously ) . 4 . Breast size ≥D 5 . BMI≤ 32 1 . Pregnant lactate woman . 2 . Subject history surgical procedure involve ribs rib cage . 3 . Subject documented osteoporosis ( bone density per DEXA le 1.8 ) . 4 . Subject breast implant . 5 . Subject suffer breast carcinoma residual malignant tumor side symmetrisation . 6 . Subject suffer reconstruction failure , skin necrosis implant infection . 7 . Subject diagnose suspect autoimmune disease . 8 . Subject pathology affect blood coagulation , immune system treatment interfere . 9 . Subject lesion due radiation , ulceration , vascular anomaly history circulatory disorder . 10 . Subject suffer progressive fibrocystic disease , consider precancerous , without mastectomy . 11 . Subject concurrent disease determine surgeon pose unduly high risk surgical and/or postoperative complication obesity , smoking , diabetes , autoimmune disease , coagulopathy , chronic lung severe cardiovascular disease . 12 . Use drug might result high surgical risk and/or significant postoperative complication , include drug would interfere blood clotting . 13 . Psychological instability , inappropriate attitude motivation . 14 . Subject participate participate one month prior plan procedure , another investigational study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>